BEHIND THE NEWS: Setbacks up pressure on Eli Lilly scientists
Hoosiers fretting over Eli Lilly and Co.’s future have new reasons to worry. Even in the best of times, the pharmaceutical business is a highstakes gambit, with every company’s fate hinging on ushering new blockbusters through its R&D pipeline. But those stakes never have been higher at Lilly, which faces a devastating onslaught of patent expirations between now and 2014. The problem isn’t just Zyprexa, the antipsychotic that loses U.S. and European protection in 2011. It accounted for 26 percent…